Ovarian steroidogenesis regulation

"Ovarian steroidogenesis regulation" is not a single molecule or receptor but rather refers to a complex biological process involving multiple cell types (granulosa and theca cells), signaling pathways (notably those mediated by LH and FSH), and a suite of enzymes responsible for converting cholesterol into biologically active steroids such as estradiol and progesterone. This process is essential for normal female reproductive function—including follicular development, ovulation, uterine preparation for pregnancy—and is tightly regulated at both transcriptional and post-translational levels. Key regulatory molecules include StAR protein (which mediates cholesterol transport into mitochondria), cytochrome P450 family members like CYP11A1/CYP17A1/CYP19A1 that catalyze specific steps in steroid biosynthesis, as well as various kinases such as ERK/MAPK that modulate enzyme expression in response to hormonal cues. Dysregulation can contribute to infertility or diseases like ovarian cancer. Therapeutic interventions target this pathway using exogenous hormones or modulators to correct deficiencies or alter reproductive outcomes. Because "Ovarian steroidogenesis regulation" describes a pathway/process rather than an individual molecular target suitable for drug binding or direct therapeutic intervention—such as an enzyme ("CYP19A1/aromatase") or receptor ("Follicle-stimulating hormone receptor")—this entry should be flagged as incorrect if used where a canonical molecular target name is required.

Drugs modulate the activity of key enzymes and signaling pathways involved in the synthesis and conversion of cholesterol to steroid hormones, often by mimicking or enhancing the action of endogenous gonadotropins such as LH and FSH